Clinical

Videos

Vikram Narayan, MD, details the little-known fact that tobacco cessation is a leading preventative strategy of bladder cancer recurrence.

Impact of Tobacco Cessation on the Development of Bladder Cancer

Vikram Narayan, MD, expanded on his data regarding nadofaragene and NMIBC published at this year’s SUO Meeting.

Narayan on Complete Responses, Biomarkers, and Side Effects of Nadofaragene Treatment for NMIBC

Narayan expanded on the other studies he contributed to from SUO investigating nadofaragene for patients with NMIBC.

Vikram Narayan, MD, Discusses Nadofaragene, Anti-Adenovirus Antibodies and Cystectomy for Patients with NMIBC

At the 2020 SUO Meeting, Vikram M. Narayan, MD, spoke about the preliminary finds of his work with nadofaragene firadenovec.

Vikram M. Narayan, MD, on Nadofaragene Firadenovec Efficacy Across Different Patient Subgroups for NMIBC 

Narayan discusses what he thinks the future of nadofaragene firadenovec and bladder cancer are at this year’s SUO Meeting.

Vikram Narayan, MD, on the Future of Nadofaragene Firadenovec and Bladder Cancer

Articles

Patients who underwent pouch diversion reported significantly more regret than patients undergoing neobladder or ileal conduit.

Pouch Diversion May Lead to Decision Regret in Patients Undergoing Cystectomy

Data for a key study secondary outcome measure showed that 56.1% of patients who achieved a complete response to Jelmyto maintained that response at 12 months.

Jelmyto Induces Durable Responses in Low-Grade UTUC 

“Providers should consider using BLC for surveillance of high-risk NMIBC patients undergoing BCG as it could change clinical management by identifying patients who are BCG unresponsive and eligible for alternative therapy and clinical trials,” said Meera Chappidi, MD.

Blue Light Cystoscopy May Help to Identify Bladder Cancer Recurrence Post-BCG

The efficacy of the novel intravesical gene-mediated therapy nadofaragene firadenovec was sustained across subgroups of patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer.

Nadofaragene Firadenovec Sustains Efficacy in BCG-Unresponsive NMIBC Subgroups

This study found that radiation therapy may provide some benefit for patients with high-risk non–muscle invasive bladder cancer, though the quality of evidence in this current setting is low.

Bladder Cancer | Topics